BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25297755)

  • 1. [Treatment strategy of gray zone lymphomas].
    Maruyama D
    Rinsho Ketsueki; 2014 Oct; 55(10):1912-9. PubMed ID: 25297755
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
    Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
    Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment strategy of Hodgkin lymphoma].
    Nagai H
    Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
    Reiter A; Schrappe M; Parwaresch R; Henze G; Müller-Weihrich S; Sauter S; Sykora KW; Ludwig WD; Gadner H; Riehm H
    J Clin Oncol; 1995 Feb; 13(2):359-72. PubMed ID: 7844597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult Burkitt lymphoma: advances in diagnosis and treatment.
    Aldoss IT; Weisenburger DD; Fu K; Chan WC; Vose JM; Bierman PJ; Bociek RG; Armitage JO
    Oncology (Williston Park); 2008 Nov; 22(13):1508-17. PubMed ID: 19133605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-hodgkins lymphoma.
    Mead G; Woodcock J; Young C
    Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recent advances and the treatment strategies of AIDS-related malignant lymphoma].
    Okada S
    Rinsho Ketsueki; 2008 Oct; 49(10):1490-8. PubMed ID: 18833933
    [No Abstract]   [Full Text] [Related]  

  • 10. [Standard or up-to-date treatment for high risk, relapsed and refractory DLBCL].
    Kagami Y
    Rinsho Ketsueki; 2010 Oct; 51(10):1409-16. PubMed ID: 20962474
    [No Abstract]   [Full Text] [Related]  

  • 11. [Management of diffuse large B-cell lymphoma in the rituximab era].
    Kinoshita T
    Rinsho Ketsueki; 2009 Oct; 50(10):1342-50. PubMed ID: 19915341
    [No Abstract]   [Full Text] [Related]  

  • 12. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of B-cell non-Hodgkin lymphoma protocol CCCG-B NHL97: a report from Chinese multi-center cooperative group.
    Tang JY; Pan C; Chen J; Chen H; Wu Y; Xue H; Zhao H; Gu LJ; Fu RY; Wang YP
    Med Pediatr Oncol; 2002 Sep; 39(3):212-4. PubMed ID: 12210455
    [No Abstract]   [Full Text] [Related]  

  • 14. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
    Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
    Czuczman MS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-46-52. PubMed ID: 23570100
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary Burkitt's lymphoma of the ovary.
    Cyriac S; Srinivas L; Mahajan V; Sundersingh S; Sagar TG
    Afr J Paediatr Surg; 2010; 7(2):120-1. PubMed ID: 20431226
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
    Bron D; Vandenheule B; Stryckmans P
    Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.